You are here
Media Advisory
Monday, November 13, 2017
Data from landmark ËÄ»¢Ó°Ôºblood pressure study supports important part of new AHA/ACC hypertension guidelines
What
Findings from a landmark study funded by the ËÄ»¢Ó°Ôº (NIH) support a key component of Ìýthe new 2017 Hypertension Clinical Practice Guidelines announcedÌý by the American Heart Association (AHA) and the American College of Cardiology (ACC) at the annual AHA meeting in Anaheim, California.
In 2013, the National Heart, Lung, and Blood Institute (NHLBI), part of the NIH, adapted to changing times and refined its focus to generating high quality scientific evidence in support of the development of clinical practice guidelines worthy of the public trust. The new high blood pressure guidelines illustrate the utility and impact of NHLBI scientific studies.
Today the AHA and the ACC issuedÌý the first comprehensive new high blood pressure guidelines in more than a decade that indicateÌý high blood pressure should be treated earlier with lifestyle changes and in some patients with medication – at 130/80 mm Hg rather than 140/90. An important component of these guidelines was informed by the results of the Systolic Blood Pressure Intervention Trial (SPRINT), a clinical study sponsored in part by the NHLBI and designed to determine the best way to treat blood pressure in adults with hypertension, 50 years or older, who are at high risk for heart disease.
SPRINT, which began in the fall of 2009, included more than 9,300 participants, recruited from about 100 medical centers and clinical practices throughout the United States. It remains the largest study of its kind to date to examine how maintaining systolic blood pressure at a lower than previously recommended level would impact cardiovascular and kidney diseases.
The pace of scientific advances today requires systematic synthesis for developing guidelines that will assist busy practitioners. The successful implementation of these guidelines will lead to improvements in the health of the nation and reduce the risks posed by heart disease and stroke. Heart disease is the United States’ leading cause of death.
In addition to primary sponsorship by the NHLBI, SPRINT is also co-sponsored by the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Neurological Disorders and Stroke and The National Institute on Aging.
Who
Dr. David Goff, Director, Division of Cardiovascular Sciences, NHLBI, is available to comment on the SPRINT study and its relationship to the new high blood pressure guidelines.
Contact
For more information or to schedule an interview, please contact the NHLBI Office of Science Policy, Engagement, Education, and Communications at 301-496-5449 or Ìýnhlbi_news@nhlbi.nih.gov.Ìý
About the National Heart, Lung, and Blood Institute (NHLBI): NHLBI, a part of the ËÄ»¢Ó°Ôº (NIH), plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at .
About the ËÄ»¢Ó°Ôº (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. ËÄ»¢Ó°Ôºis the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about ËÄ»¢Ó°Ôºand its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®